نتایج جستجو برای: oncolytic viruses

تعداد نتایج: 102002  

Journal: :Polymer chemistry 2014
Eduardo Ruiz-Hernández Michael Hess Gustavo J Melen Benjamin Theek Marina Talelli Yang Shi Burcin Ozbakir Erik A Teunissen Manuel Ramírez Diana Moeckel Fabian Kiessling Gert Storm Hans W Scheeren Wim E Hennink Aladar A Szalay Jochen Stritzker Twan Lammers

An enzymatically activatable prodrug of doxorubicin was covalently coupled, using click-chemistry, to the hydrophobic core of poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl)-methacrylamide-lactate] micelles. The release and cytotoxic activity of the prodrug was evaluated in vitro in A549 non-small-cell lung cancer cells after adding β-glucuronidase, an enzyme which is present intracellularly i...

Journal: :Journal of the National Cancer Institute 2007
Jung Hyo Rhim Giovanna Tosato

Virus-mediated oncolysis is not a new concept. The idea goes back to the early 1900s, when it was noted that a flu-like disease coincided with a substantial drop in the number of tumor cells in a leukemic patient (1) and that rabies vaccination was followed by regression of cervical cancer (2). Additional anecdotal observations followed, but early attempts at viral therapy for cancer were unsuc...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2014
Yuan Lin Haipeng Zhang Jiankai Liang Kai Li Wenbo Zhu Liwu Fu Fang Wang Xiaoke Zheng Huijuan Shi Sihan Wu Xiao Xiao Lijun Chen Lipeng Tang Min Yan Xiaoxiao Yang Yaqian Tan Pengxin Qiu Yijun Huang Wei Yin Xinwen Su Haiyan Hu Jun Hu Guangmei Yan

Oncolytic virotherapy is a growing treatment modality that uses replicating viruses as selective antineoplastic agents. Safety and efficacy considerations dictate that an ideal oncolytic agent would discriminate between normal and cancer cells on the basis of common genetic abnormalities in human cancers. Here, we identify a naturally occurring alphavirus (M1) as a novel selective killer target...

Journal: :Current cancer drug targets 2007
Wang Yu Hu Fang

Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. Fro...

2017
Irina Kuznetsova Tobias Arnold Thomas Aschacher Cornelia Schwager Balazs Hegedus Tamas Garay Marina Stukova Maria Pisareva Stephan Pleschka Michael Bergmann Andrej Egorov

Oncolytic viruses are currently established as a novel type of immunotherapy. The challenge is to safely target oncolytic viruses to tumors. Previously, we have generated influenza A viruses (IAVs) containing deletions in the viral interferon antagonist. Those deletions have attenuated the virus in normal tissue but allowed replication in tumor cells. IAV entry is mediated by hemagglutinin (HA)...

2014
Ramon Alemany

The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic adminis...

Journal: :Journal of virology 2012
Andrea M Murphy Dahlia M Besmer Megan Moerdyk-Schauwecker Natascha Moestl David A Ornelles Pinku Mukherjee Valery Z Grdzelishvili

Vesicular stomatitis virus (VSV) is a promising oncolytic agent against a variety of cancers. However, it has never been tested in any pancreatic cancer model. Pancreatic ductal adenocarcinoma (PDA) is the most common and aggressive form of pancreatic cancer. In this study, the oncolytic potentials of several VSV variants were analyzed in a panel of 13 clinically relevant human PDA cell lines a...

2017
Beata Urszula Orzechowska Marcin Jędryka Katarzyna Zwolińska Rafał Matkowski

The standard approach to treating patients with advanced epithelial ovarian cancer (EOC) after primary debulking surgery remains taxane and platinum-based chemotherapy. Despite treatment with this strategy, the vast majority of patients relapse and develop drug-resistant metastatic disease that may be driven by cancer stem cells (CSCs) or cancer initiating cells (CICs). Oncolytic viruses circum...

2017
Zeeshan Ahmad Robert A Kratzke

Oncolytic virotherapy is the use of replication-competent viruses to treat malignancies. The potential of oncolytic virotherapy as an approach to cancer therapy is based on historical evidence that certain viral infections can cause spontaneous remission of both hematologic and solid tumor malignancies. Oncolytic virotherapy may eliminate cancer cells through either direct oncolysis of infected...

2014
Padma Sampath Steve H Thorne

The field of oncolytic virology has made great strides in recent years. However, one key finding has been that the use of viral agents that replicate selectively in tumors is usually insufficient to achieve anything beyond small and transient responses. Instead, like most cancer therapies, oncolytic viruses are most effective in combination with other therapies, which is where they have proven ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید